• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

May 20, 2019
Company Drug/Device Medical Condition Status
Tolero Pharmaceuticals, Inc. TP-3654 advanced solid tumors Phase I trial initiated
Tempest Therapeutics Inc. TPST-1120 advanced solid tumor malignancies Phase I/Ib trial initiated enrolling subjects with advanced solid tumors
ORIC Pharmaceuticals ORIC-101 in combination with nab-paclitaxel advanced solid tumors Phase Ib trial initiated
InflaRx IFX-1 ANCA-associated vasculitis (AAV) Phase II trial initiated enrolling 80 subjects at 60 sites across 12 European countries and Russia
Rigel Pharmaceuticals, Inc. fostamatinib disodium hexahydrate (fostamatinib) warm antibody autoimmune hemolytic anemia (AIHA) Phase III trial initiated enrolling 80 subjects in the U.S.
ReGenTree, LLC RGN-259 eye drops dry eye syndrome Phase III trial initiated enrolling 700 subject at 15 sites in the U.S.
Haemonetics Corporation 6s Hemostasis Analyzer System adult trauma 510(k) clearance granted by the FDA
Transgene TG4050 ovarian cancer IND approval granted by the FDA
Merz Americas XEOMIN (incobotulinumtoxinA) blepharospasm (involuntary blinking) sBLA approval granted by the FDA
AliveCor KardiaMobile 6L six-lead personal ECG device cardiovascular disease Clearance granted by the FDA
Genentech and AbbVie Venclexta (venetoclax) in combination with Gazyva (obinutuzumab) previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) Approval granted by the FDA
EMD Serono and Pfizer, Inc. BAVENCIO (avelumab) in combination with INLYTA (axitinib) advanced renal cell carcinoma (RCC) Approval granted by the FDA
Eli Lilly and Company CYRAMZA (ramucirumab injection, 10 mg/mL solution) hepatocellular carcinoma (HCC) Approval granted by the FDA
Regeneron Pharmaceuticals, Inc. EYLEA (aflibercept) Injection diabetic retinopathy (DR) Approval granted by the FDA

 

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing